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Abstract
Introduction: A high recurrence rate of hepatocellular carcinoma (HCC) remains a significant concern.
The risk factors for recurrence were analysed and the optimal surgical approaches were investigated.
Methods: The subjects comprised 280 consecutive patients with primary solitary HCC measuring
5 cm in diameter, who underwent curative resections. Multivariate analysis was conducted to identify
the risk factors for post-operative recurrence, and the clinical significance of an anatomic resection was
evaluated.
Results: Multivariate analysis identified HCV infection, a des-gamma-carboxyprothrombin level
>100 mAU/ml, underlying cirrhosis, the presence of microvascular invasion, the presence of microme-
tastases and non-anatomic resection as being significant risk factors for post-operative recurrence. The
5-year recurrence rate was 56.7% in the anatomic resection (AR) group and 74.7% in the non-AR group.
The 5-year survival rate was 82.2% in the AR group and 71.9% in the non-AR group. Local recurrence
within the same segment was observed in 25% of the patients of the non-AR group. The prognostic
superiority of AR was confirmed only in patients with histopathological evidence of microvascular
invasion and/or micrometastases, and in patients having a solitary HCC measuring 2 to 5 cm in diameter.
Conclusions: Anatomic resection may decrease local recurrence and improve the surgical outcomes in
solitary HCC measuring 2 to 5 cm in diameter.
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Introduction
In spite of the recent improvements in the therapeutic strategies
for hepatocellular carcinoma (HCC),1 the cumulative recurrence
rate of HCC remains as high as 50%–60% at 3 years and 70%–
100% at 5 years, even after curative liver resection.2–7
To date, various factors influencing the risk of recurrence of
HCC have been reported, including tumour size,8–10 tumour
number,8–11 vascular invasion,8,12–15 the presence of satellite
nodules,16,17 histopathological grade,11 underlying cirrhosis16,17
and the type of surgery (i.e. major vs. minor resections, anatomic
vs. non-anatomic resections, wide vs. narrow surgical margins,
etc.).4,18–21 Nevertheless, it still remains under debate as to what
extent the surgical strategy might contribute to reducing the risk
of intrahepatic tumour recurrence.
Recent studies have shown that systematic resection of the
tumour-bearing portal territory (anatomic resection) may
improve the disease-free survival,4,18,20,22–26 and even the overall
survival,18,22,25,26 in patients with HCC. The rationale for anatomic
resection of the tumour-bearing portal territory is that HCCs tend
to spread intrahepatically via portal venous tributaries. However,
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only a few clinicopathological reports are available with regard to
the local recurrence rate after anatomic resection23,25 or the actual
distribution of micrometastases around the tumour.24 The pur-
poses of this study were to revisit the risk factors for intrahepatic
tumour recurrence after surgical resection of HCC and to inves-
tigate the optimal surgical approach based on the clinicopatho-
logical outcomes.
Patients and methods
Study population
The subject pool consisted of 494 consecutive patients who under-
went curative liver resection for primary and solitary HCC
between January 1994 and December 2008 at the University of
Tokyo Hospital. Among these, the patients who were found to
have vascular tumour thrombosis on pre-operative imaging (n =
93) or had a history of other malignancy within 5 years prior to
the surgery (n = 17) were excluded from the analysis. In addition,
to clearly determine the clinical significance of Couinaud’s seg-
mentectomy, HCC patients with tumours measuring >5 cm in
diameter (n = 104) were also excluded, based on the finding from
our prospective database since 1994, that only 14.8% of patients
with HCCs exceeding 5 cm in tumour diameter were treatable by
Couinaud’s segmentectomy, and that the remaining 85.2%
required extended resection of 2 or more segments. The remain-
ing 280 patients, consisting of 210 men (75.0%) and 70 women
(25.0%), ranging in age from 13 to 85 years (median age, 65), were
enrolled in the present analysis.
Surgical treatment
The indication for surgery was based on an algorithm including
the presence/absence of ascites, the serum total bilirubin level
and the results of the indocyanine green retention test, as previ-
ously described.8,18 Given the fact that HCC has a high propensity
to invade the portal veins, and that intrahepatic metastasis via the
portal venous tributaries is one of the major mechanisms of
recurrence, systematic resection of the tumour-bearing portal
regions was performed in the patients, as long as the procedure
was permitted by the functional reserve of the liver.27
Anatomic resection (AR) was defined as any type of systematic
resection of the portal regions based on Couinaud’s classification.
Technically, the procedure for AR includes the following four
steps: (i) confirmation and marking of the segmental border on
the liver surface by a segmental staining method28,29 or by occlu-
sion of the segmental inflow; (ii) parenchymal transection from
the segmental border to the landmark veins under ultrasound
guidance;28 (iii) full exposure of the landmark veins on the cut
surface of the liver; and (iv) ligation of the segmental portal
pedicle near the root of the segment. In this study, only the sur-
gical manoeuvres where all of these four steps were completed
were classified as AR. Other surgical manoeuvres, including
incomplete removal of the tumour-bearing portal regions, such as
wedge resection or enucleation, were classified as a non-anatomic
resection (non-AR).
Histopathological classification
The tumour size and width of the surgical margin were recorded
before the specimens were fixed. The histological grade of differ-
entiation of the tumour, the degree of fibrosis in the background
liver and the presence/absence of vascular invasion were also
assessed microscopically based on the classification system pro-
posed by the Liver Cancer Study Group of Japan.30 A diagnosis of
liver cirrhosis was based on histopathological evidence of grade 4
fibrosis according to Desmet’s classification.30,31
Patient follow-up
All the patients were regularly screened for recurrences through
monitoring of the plasma levels of the HCC-specific tumour
markers, alpha-fetoprotein (AFP) and des-g-carboxyprothrombin
(DCP), every 1–2 months, ultrasonography every 2 months and
dynamic computed tomography every 4 months, as previously
reported.32 Recurrence was defined as the appearance of a new
lesion having radiological features compatible with HCC, as con-
firmed using at least two imaging modalities. When a recurrence
was detected, the patient received further treatment by repeat
hepatectomy, locoregional ablation therapies including radiofre-
quency ablation (RFA), transcatheter arterial chemoembolization
(TACE) or other treatment options, as indicated. In the present
study, the recurrence-free survival period was defined as the inter-
val between the operation and the date of the diagnosis of the first
recurrence (either intrahepatic or extrahepatic). The remaining
cases were censored at the date of the last follow-up examination.
Data analysis
Statistical analysis was performed using the IBM SPSS software
(version 19.0; SPSS Inc., Chicago, IL, USA). The medians and
ranges of continuous data were compared using the Mann–
Whitney U-test. Categorical data were compared using Pearson’s
chi-squared test or Fisher’s exact test, as appropriate. P-values of
<0.05 were considered to be statistically significant.
Survival curves were generated using the Kaplan–Meier method
and compared by the log-rank test. To identify the risk factors for
tumour recurrence, a multivariate regression analysis was per-
formed using the Cox proportional hazard model with backward
elimination, using variables with P < 0.20 in the univariate analy-
sis. All the analyses in this study were performed in accordance
with the ethical guidelines for clinical studies at the University of
Tokyo Hospital.
Results
Overview
The clinicopathological characteristics of the study population are
summarized in Table 1. During the median follow-up period of
57.6 months (range, 1–186.8), 165 patients (58.9%) developed
tumour recurrence and 75 patients (26.8%) died. Among the 205
censored cases, 37 patients (18%) were lost to follow-up during
the study period. The 1-, 3-, and 5-year survival rates were 98.9%,
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90.9%, and 78.6%, respectively, and the cumulative recurrence
rates were estimated to be 16.8% at 1 year, 50.6% at 3 years and
62.8% at 5 years.
Risk factors for post-operative recurrence
To identify the risk factors for post-operative recurrence, the
cumulative recurrence rates were compared for 18 clinically plau-
sible factors (Table 2). Of these factors, the 11 items with P < 0.20
in the univariate analysis were selected as variables for inclusion in
the multivariate regression analysis. The multivariate regression
analysis using the Cox proportional hazard model with backward
elimination identified the following six variables as independent
risk factors for tumour recurrence: HCV infection, plasma DCP >
100 mAU/ml, the presence of underlying cirrhosis, the presence of
microscopic vascular invasion, the presence of micrometastases
and non-AR.
Comparison of anatomic and non-anatomic resections
The 1-, 3-, and 5-year survival rates were 99.4%, 92.2%, and 82.2%
in the AR group, and 97.8%, 88.5%, and 71.9% in the non-AR
group, respectively (P = 0.182) (Fig. 1). The 1-, 3- and 5-year
recurrence rates were 16.6%, 44.6% and 56.7% in the AR group,
and 17.2%, 61.9% and 74.7% in the non-AR group, respectively
(P = 0.009). In the post-hoc analysis, the statistical powers to
detect a difference of survival at 5 years and recurrence at 3 years
at P = 0.05 were estimated as 52.6% and 74.8%, respectively.
A comparison of the patient characteristics between the AR and
non-AR groups is shown in Table 3. Child–Pugh class B and liver
cirrhosis were more prevalent, and the surgical margin tended to
be smaller, in the non-AR group as compared with the AR group.
However, when the groups were stratified by the width of the
surgical margin (0 mm vs. >0 mm) and state of the background
liver (cirrhosis vs. non-cirrhosis), a similar tendency, that is, of AR
being superior to non-AR in respect of the tumour recurrence
rate, was confirmed, regardless of the width of the surgical margin
or state of the background liver.
Patterns of recurrence
The tumour recurrence patterns and initial treatments adminis-
tered for recurrent lesions are summarized in Table 4. During the
study period, recurrence was detected in 100 patients (54.3%) in
the AR group and 65 patients (67.7%) in the non-AR group. The
median time to recurrence was remarkably shorter in the non-AR
group. Although the number and distribution of the recurrent
nodules based on the segmental anatomy were similar between the
two groups, local recurrence within the same portal segment was
observed in 24 patients (25%) in the non-AR group, accounting
for 37.5% of all tumour recurrences in this group. The interval
from surgery to recurrence in the patients with local recurrence
was significantly shorter as compared with that in the patients
without local recurrence (13.2 months vs. 23.6 months, P =
0.001). Among the 24 patients with local recurrence, 19 patients
developed the recurrence within 24 months after the surgery.
When the patients with local recurrence were excluded, the cumu-
lative recurrence curve of the non-AR group became similar to
that of the AR group (Fig. 2).
Efficacy of anatomic resection
To clarify under what circumstances AR might be truly effective,
the efficacy of AR was investigated according to the presence/
absence of microscopic cancer spread32 (i.e. microvascular inva-
sion and/or micrometastases) and currently used size cut-off
value for early HCC.33,34 As shown in Fig. 3a–b, AR was superior
only in patients with histopathologically proven microscopic
cancer spread, and among the patients showing no histopatho-
Table 1 Patient characteristics (n = 280)
Age, median (range) 65 (13–85)
Gender, male 210 (75.0)
HBsAg positive 59 (21.1)
HCV-Ab positive 174 (62.1)
Child–Pugh
A 245 (87.5)
B 35 (12.5)
Tumour size (mm), median (range) 28 (8–50)
Types of surgery
Non-anatomic resection 96 (34.3)
Anatomic resection 184 (65.7)
Segmentectomy 151
Sectorectomy 23
Hemihepatectomy 10
AFP (ng/ml), median (range) 16 (1–37081)
DCP (mAU/ml), median (range) 36 (0–23630)
Macroscopic typesa
VN or SN 175 (63.2)
SNEG 65 (23.5)
CM 36 (13.0)
unknown 4 (1.4)
Capsule formation 215 (77.1)
Histological grade
Well 54 (19.8)
Moderate 194 (71.1)
Poorly/undifferentiated 25 (9.2)
Unknown 7 (2.5)
Microscopic invasion or metastasis 76 (27.1)
Parentheses represent percentage unless indicated.
aClassification of Liver Cancer Study Group of Japan.30
HBsAg: hepatitis B surface antigen, HCV-Ab: anti-hepatitis C antibody,
AFP: alpha-fetoprotein, DCP: des-g-carboxyprothrombin, VN: vague
nodular type, SN: simple nodular type, SNEG: simple nodular type with
extranodular growth, CM: confluence multinodular type.
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logical evidence of microscopic tumour spread, there was no sig-
nificant difference in the outcomes between the two surgical
manoeuvres. Regarding the influence of the tumour size, AR was
effective in HCC patients with tumours measuring 2 to 5 cm in
diameter, whereas no significant difference in the tumour recur-
rence rate was observed between the two surgical manoeuvres in
HCC patients with tumours measuring 2 cm in tumour diam-
eter (Fig. 3c–d).
Table 2 Risk factors of tumour recurrence
n Recurrence-free survival
median (95% CI)
Univariate analysis Multivariate analysis
P HR 95% CI P HR 95% CI
Age >65 136 38.7 (28.0–51.1) 0.992
65 144 32.4 (26.7–44.9)
Gender Male 210 35.6 (25.8–47.2) 0.966
Female 70 37.9 (25.8–50.0)
HBsAg + 59 41.0 (26.7–69.9) 0.251
- 221 34.3 (28.8–42.8)
HCV-Ab + 174 29.1 (24.0–37.9) 0.003 1.64 1.18–2.30 0.001 1.79 1.27–2.52
- 106 55.5 (35.6–69.9)
Child–Pugh B 245 38.7 (28.9–50.4) 0.608
A 35 32.1 (24.0–37.9)
Background liver LC 129 50.4 (28.9–80.6) 0.017 1.46 1.07–2.00 0.027 1.44 1.04–1.99
non LC 151 32.4 (24.7–38.9)
Maximum diameter >2 cm 202 35.6 (27.3–48.9) 0.195 1.25 0.98–1.80 0.631
2 cm 78 38.7 (28.8–64.7)
Gross classification a SNEG or CM 102 27.3 (21.0–48.3) 0.246
VN or SN 175 40.7 (32.4–55.5)
Capsule formation + 305 50.4 (33.3–69.4) 0.084 0.74 0.53–1.02 0.062
- 78 28.8 )24.0–35.6)
Differentiation mod/por 54 29.9 (18.8–51.1) 0.433
Wel 219 37.9 (28.9–50.0)
Microvascular invasion + 60 28.8 (14.9–40.7) 0.022 1.57 1.07–2.26 0.049 1.50 1.02–2.22
- 220 38.1 (30.0–55.5)
Micrometastases + 24 12.9 (6.6–25.8) 0.004 2.24 1.33–3.57 0.004 2.09 1.26–3.46
- 256 38.1 (30.3–48.9)
AFP (ng/ml) >20 125 35.8 (32.1–40.7) 0.189 1.22 0.90–1.67 0.751
20 155 41.0 (32.1–59.4)
DCP (mAu/ml) >100 79 24.0 (16.9–58.1) 0.037 1.44 1.02–2.00 0.007 1.64 1.14–2.36
<100 201 38.9 (30.3–50.0)
Types of resection Non-anatomic 96 28.8 (22.3–35.8) 0.011 1.51 1.10–2.07 0.017 1.48 1.07–2.03
Anatomic 184 47.2 (30.4–64.4)
Transfusion + 7 37.9 ( 6.0–65.7) 0.630 1.29 0.40–3.05
- 259 35.9 (29.1–47.2)
Tumour exposure b + 65 25.5 (19.6–39.9) 0.012 1.57 1.11–2.20 0.200
- 215 38.1 (30.0–57.9)
Surgical margin +1 mm 0.065 0.98 0.95–1.00 0.857
Boldfaced entries represent significant factors in the final model.
aClassification of the Liver Cancer Study Group of Japan.30
bExposure of the tumour capsule on the cut surface of the liver.
AFP, alfa-fetoprotein; DCP: des-gamma carboxyprothrombin; LC, liver cirrhosis; SNEG: simple nodular type with extranodular growth; CM, confluent
multinodular type; VN, vague nodular type; SN, simple nodular type, wel/mod/por: well/moderately/poorly differentiated hepatocelluar carcinoma;
HR, hazard ratio; 95% CI, 95% confidence interval.
34 HPB
HPB 2013, 15, 31–39 © 2012 International Hepato-Pancreato-Biliary Association
Discussion
In this study, the prognostic factors were analysed in patients with
HCC having a solitary tumour measuring5 cm in diameter who
were treated by resection. The findings revealed that HCV infec-
tion, high plasma DCP levels, underlying cirrhosis, the presence of
microvascular invasion and the presence of micrometastases were
significant risk factors for post-operative recurrence of HCC. Also,
anatomic resection was identified as the only modifiable factor to
decrease the rate of recurrence. Comparison of the AR and
non-AR groups revealed significantly higher recurrence rates in
the non-AR group, although the difference in the overall survival
between the two groups was not significant. The main clinico-
pathological differences between the two groups were the shorter
time from surgery to recurrence and the higher local recurrence
rate in the patients who had undergone non-AR. The prognostic
advantage of AR was only observed in HCC patients with his-
topathologically proven microscopic cancer spread and in those
with a solitary tumour measuring 2 to 5 cm in diameter.
Favourable outcomes of AR as the surgical strategy for HCC
have been reported by several recent studies.4,18,22–26,35 However, the
oncological superiority of AR has been discussed mainly from the
point of view of the long-term outcomes after surgery, and little
clinicopathological evidence has been reported23–25 to justify the
adoption of AR as the preferred surgical resection strategy for
HCC. Therefore, the current study focused on the difference in the
pattern of recurrence and histopathological findings between the
AR and non-AR groups, to clarify the clinicopathological bases for
the prognostic difference between the two surgical strategies.
Comparison of the AR and non-AR groups revealed that AR was
superior to non-AR in terms of the tumour recurrence rate, inde-
pendent of the width of the surgical margin (0 mm vs. >0 mm) or
the histopathological characteristics of the background liver (cir-
rhosis vs. non-cirrhosis). Although the survival difference was not
statistically significant, the 5-year survival rates exceeded 70% in
both the groups, and post-hoc analysis revealed that the current
population size was insufficient to show the survival difference
with adequate statistical power in the background of such a high
survival rate.
In the comparison to the mode of recurrence, no significant
differences were observed in the size, number or distribution of
the recurrent lesions. However, local recurrence within the same
portal segment was observed in 25% of the patients after non-AR,
and these patients were characterized by very early recurrence,
with a median interval from surgery to recurrence of 13.2 months;
these findings suggested that these recurrences had probably
originated from undetectable residual micrometastases within the
remaining part of the liver parenchyma. Interestingly, when the
patients with local recurrence were excluded, the cumulative
recurrence rate in the non-AR group became similar to that in the
AR group. Furthermore a subset analysis revealed that AR was
superior only in patients with histopathological evidence of
microscopic cancer spread. These results suggest that the onco-
logical superiority of AR was attributable to the reduced incidence
of local recurrence associated with eradication of micrometastases
within the tumour-bearing portal segment in AR. Similar results
have been reported from recent studies that have explored the
clinicopathological basis for the oncological advantage of AR.23–25
Regarding the width of the surgical margin, there was a signifi-
cant difference between the AR and non-AR groups (median
width, 5 mm vs. 1 mm). However, the difference was rather small
and the rate of tumour exposure on the cut surface of the liver was
relatively high in both the AR and non-AR groups. These observa-
tions may be attributable to the fact that extended resection beyond
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the segmental border is not always possible in patients with cirrho-
sis, as a result of the limited hepatic functional reserve. For
example, when a tumour is attaching to the major hepatic veins or
the inferior vena cava, extended resection or en-bloc resection of
the veins is not always possible, especially in patients with a mar-
ginal hepatic functional reserve. In such cases, the tumour is care-
fully detached from the vein, while exercising special caution to
avoid injury to the tumour capsule. Indeed, as shown by the results
of the multivariate analysis, the tumour recurrence rate was not
correlated with either exposure of the tumour capsule or the width
of the surgical margin, as long as the capsule was not injured. In
addition, a subset analysis revealed that AR was associated with a
lower recurrence rate, regardless of the exposure of the tumour
capsule on the cut surface of the liver. These results indicate that
systematic removal of the tumour-bearing portal segments may be
more important than securing a sufficient surgical margin to
reduce the post-operative recurrence of HCC.
Recently, a retrospective study using a large cohort conducted
by the Liver Cancer Study Group of Japan reported that AR may
be effective in a specific group of HCC patients with tumours
measuring 2 to 5 cm.20 As shown in Fig. 3, similar results were
obtained in the current study. AR was clearly effective in HCC
patients bearing a solitary tumour measuring 2 to 5 cm, whereas
among the patients with a maximum diameter of the tumour
nodules of 2 cm, there was no significant difference in the post-
operative recurrence rate between the AR and non-AR groups.
Therefore, AR should be considered as the preferred surgical strat-
egy, especially in HCC patients having a solitary tumour measur-
Table 3 Comparison of clinicopathological characteristics between the patients with anatomic and non-anatomic resections
Anatomic resection Non anatomic resection P
N 184 96
Age, median (range) 66 (13–85) 64 (16–81) 0.404
Gender, male 138 (75.0) 72 (75.0) 1.000
HBsAg 43 (23.4) 16 (16.7) 0.192
HCV-Ab 112 (60.9) 62 (64.6) 0.543
Child–Pugh A/B 174 (94.6)/10 (5.4) 71 (74.0)/25 (26.0) <0.001
Size (mm) 39 (8–50) 28 (8–50) 0.991
Macrostopic typea
VN or SN 112 (60.5) 63 (65.6) 0.748
SNEG 45 (24.5) 20 (20.8)
CM 23 (12.5) 13 (13.5)
Others 4 (2.2) 0 (0)
Histological grade
Well 36 (20.0) 18 (19.4) 0.913
Moderate 129 (71.7) 65 (69.9)
Poor 15 (8.3) 10 (10.8)
Microvascular invasion 37 (20.1) 23 (24.0) 0.456
Micrometastases 11 (11.5) 13 (7.1) 0.213
Liver cirrhosis 91 (49.5) 60 (62.5) 0.037
Surgical time (min) 315 (260–374) 275 (211–340) 0.002
Blood loss (ml) 498 (314–776) 480 (213–821) 0.449
Inflow occlusion 169 (99.4) 81 (90.0) <0.001
Transfusion 4 (2.3) 3 (3.4) 0.690
Surgical margin (mm) 1 (0–40) 5 (0–40) <0.001
Tumour exposure b 27 (14.7) 38 (39.5) <0.001
Specimen weight (g) 125 (5–920) 40 (1.5–260) <0.001
Parentheses represent percentage unless indicated.
HBsAg: hepatitis B virus surface antigen, HCV-Ab: anti hepatitis C virus antibody.
aClassification of the Liver Cancer Study Group of Japan.30
bExposure of the tumour capsule on the cut surface of the liver.
VN, vague nodular type; SN, simple nodular type; SNEG, simple nodular type with extranodular growth; CM, confluence multinodular type.
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ing 2 to 5 cm in diameter, as long as the hepatic functional reserve
permits such a surgical manoeuvre.
The limitations of this study include its retrospective nature
and imbalance of the patient population between the AR and
non-AR groups. Because selection of the surgical manoeuvre was
based on an algorithm that considered the hepatic functional
reserve,8 it is natural that patients in the non-AR group may have
a lower mean hepatic functional reserve and higher incidence of
cirrhosis. However, in our study, AR tended to be associated with
a more favourable recurrence rate than non-AR, even after adjust-
ments for the width of the surgical margin (0 mm vs. >0 mm) and
the state of the underlying liver parenchyma (cirrhosis vs. non-
cirrhosis). Also, the multivariate analysis revealed that the type
of surgical manoeuvre was independently correlated with the
tumour recurrence rate. Furthermore, based on the current analy-
sis, the prognostic difference between the AR and non-AR group
seemed to be explained mainly by the reduction of the local recur-
rence rate associated with eradication of undetectable residual
micrometastases within the tumour-bearing portal segment in the
AR group.
In conclusion, AR is the only modifiable factor that has been
shown to have the potential to decrease the post-operative recur-
rence rate in patients with HCC. The oncological advantage of AR
is related to its potential to eradicate micrometastases within the
tumour-bearing portal segment, and up to 25% of patients may be
expected to benefit from AR in terms of local recurrence. Based on
the clinical results, AR is recommended for the initial resection of
patients with HCC having a solitary tumour measuring 2 to 5 cm
in diameter, as long as such extensive resection is permitted by the
hepatic functional reserve.
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Table 4 Patterns of recurrence and treatment
Anatomic resection (n = 184) Non anatomic resection (n = 96) P
Recurrence 100 (54.3) 65 (67.7)
Time to recurrence (months) median (95% CI) 47.2 (30.4–64.4) 28.8 (22.3–35.8) 0.009
Number of recurrent nodules
Median (range) 1 (1–20) 1 (1–20) 0.978
Solitary/multiple 57 (57.0)/43 (43.0) 39 (60.9)/25 (39.9) 0.617
Site of recurrence
Intrahepatic 100 (100) 64 (98.5) 0.828
Same segment NA 24/64 (37.5) NA
Same sector 40/87 (46.0) 32/64 (50.0) 0.625
Adjacent sectors 64/100 (64.0) 44/64 (68.8) 0.531
Distant sectors 27/100 (27.0) 13/64 (20.3) 0.330
Extrahepatic 1 (1.0) 2 (3.1) 0.972
Treatment
Surgery 56 (56.0%) 20 (30.8%) 0.014
RFA 12 (12.0%) 12 (18.5%)
TACE/TAI 26 (26.0%) 31 (47.7%)
Others 6 (6.0%) 2 (3.1%)
95% CI, 95% confidence interval; SD, standard deviation; NA, not available.
Parentheses represent percentage. RFA: radiofrequency ablation, TACE: transarterial chemoembolization, TAI: transarterial infusion treatment.
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anatomic resection. AR: anatomic resection; non-AR: non-anatomic
resection
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